9 Where Sai is in its 25th Year FY 2024 Financials & Employee strength 300+ Discovery programs completed >65% Integrated Drug Discovery (IDD) >300 Active customers across Biotech, small & mid and big pharma across US, UK, EU, Japan 18 months Demonstrated time from Hit to IND 16 Tech Transfers from UK to India 10+ Years: Enduring customer relationships 20+ Assays transferred from Boston to Hyderabad 31 Commercial molecules in current portfolio of projects 11 Filed / Phase III molecules in current portfolio of projects Diverse therapy areas Oncology, CNS, Inflammation, Antivirals, Rare diseases and more 40+ Programs advanced to IND or Phase I/II/III 17/20 of the largest pharmaceutical companies are customers 5 Molecules from discovery to market $176.95 mn Revenue $141.45 mn Fixed Assets $10 mn Profit After Tax (PAT) $0.11 mn CSR Contributions Employees 2807 Manufacturing R&D Quality Others 804 287 1298 418
RkJQdWJsaXNoZXIy MTIwMDc4NQ==